Communication on the introduction of warnings and precautions for severe skin reactions with Xeloda® (capecitabine)

Roche would like to inform healthcare professionals of the introduction of warnings and precautions for severe skin reactions with Xeloda®(capecitabine). A recent review of the company safety database and literatures has identified reports of severe skin reactions such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), in some cases with a fatal outcome, during treatment with Xeloda®. The frequency of the severe skin reactions is estimated as very rare taking into account the exposure to Xeloda® as per April 2013. Healthcare professionals are advised to monitor and inform their patients on the potential causality of severe skin reactions to Xeloda® treatment. The package insert for Xeloda® will be updated to reflect the new safety information. Please refer to the Dear Healthcare Professional Letter for more details.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP). HPP is a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg/, and follow the procedures below to access the MOH Alert system.

Step 1: Scroll down to the bottom navigation panel of the HPP web page. Under the Healthcare Professionals section, expand the dropdown option for ‘Healthcare Professional Portal’ and select your profession. You will be redirected to the specific HPP web page to log in.

Step 2: Click on the Restricted Content icon on the left panel of the web page and log in via SingPass.

Step 3: Click on the MOH Alert icon under the ‘Applications’ section.

Step 4: Click on the Drug Alert tab to view the DHCPLs.